feasible. A patent is granted only when a compound's application can be classified as both 'new' and 'invented' . A highly effective compound thrown up by an AI algorithm could indeed be new. Whether it is 'invented' , however, is debatable. This is because the inventor might be considered as either the algorithm (so not a person) or its programmer.
It could be argued that if there is a connection between the program and the compound's structure, then it is predictable by experts and so no longer inventive. Or, if the programmer can't explain how the AI algorithm found the structure, then he or she didn't invent anything. Assigning and agreeing on intellectual-property rights will be even more complex when different parts of the process behind important discoveries involve multiple contributors.
Patent law would presumably have to be adapted, for example by acknowledging the development work through a temporary ban on imitation. 
Lutz Heuer

AI threat to drug development
Artificial intelligence could help to identify more-effective candidate drugs (see Nature 557, S55-S57; 2018). However, this dream held by patients, clinicians, physicians and the public-health system could become a nightmare for the pharmaceutical industry.
The development of a clinically active ingredient generally costs hundreds of millions of euros, so the compound needs to be protected by a worldwide patent for the process to be economically research. We organize meetings, student workshops, mentorship programmes and an annual training programme.
We hope to develop the skills to navigate and improve the drugdiscovery pipeline. Speeding up research delivery from bench to bedside will also entail changing how scientists are evaluated, as well as promoting collaboration across disciplines (R. Benedictus et al. Nature 538, 453-455; 2016 
Young scientists aim to prioritize patients
Translational medicine helps to prevent scientific research from being wasted by focusing on the long-term benefits for patients. As early-career researchers, we want to accelerate that process -rather than waiting for senior researchers to spearhead the necessary changes.
Our international network of aspiring clinician-scientists, called Apollo, collaborates with senior scientists from the EUREKA Institute for Translational Medicine in Syracuse, Italy. We aim to learn about the goals, opportunities and challenges of translational medicine, including finding a more-efficient way to use research funding and balancing the competing interests of the different parties involved in
Cite the online date of publication
With online delivery increasingly dominating scientific publishing, most long-established journals run papers in both print and online formats -but not necessarily simultaneously. This can affect how researchers are given scientific priority. In our view, scholars from all disciplines should use the earlier, online citation date, rather than defaulting to print as the traditional record.
In our experience, the time lag between the two can be as long as 6 months. This might be crucial for annual research evaluations, for instance, when a paper is published online at the end of one year and in print the year after (see, for example, A. L. Woerman et al. Acta Neuropathol. 135, 49-63; 2018 , originally published online in August 2017). Timings are also key when two competing groups publish papers that report similar findings. Young scientists, in particular, need to have the publication date of their original work accurately recorded.
Using the online publication date as the primary citation would dispel such confusion. Reference lists that include dates for both publication formats and are picked up by public databases such as PubMed are a step in the 
